Meeting
2017 ASCO Annual Meeting
Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303).
Authors
Ken Kato
Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan
Ken Kato , Toshihiko Doi , Takashi Kojima , Hiroki Hara , Shunji Takahashi , Kei Muro , Tomohiro Nishina , Masashi Wakabayashi , Shogo Nomura , Akihiro Sato , Atsushi Ohtsu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
UMIN000011217
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4069)
DOI
10.1200/JCO.2017.35.15_suppl.4069
Abstract #
4069
Poster Bd #
61
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2).
First Author: Reinhard Dummer
Poster
2023 ASCO Annual Meeting
Darolutamide for patients with androgen receptor positive salivary gland cancers (DISCOVARY): The results of phase 2 study of darolutamide monotherapy.
First Author: Susumu Okano
Poster
2022 ASCO Annual Meeting
Overall survival results from a phase II trial of anlotinib plus sintilimab in patients with recurrent advanced cervical cancer.
First Author: Qin Xu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
First Author: Zhiwei Chang